Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Tyler Johnson

GI Oncology · Stanford

View

Dr. James Cleary

GI Oncology · Dana-Farber Cancer Institute

View

Dr. Thorvardur Halfdanarson

GI Oncology · Mayo Clinic Rochester

View

Dr. Linette Bosques

GI Oncology · DFCI/MGB

View

Dr. Shikha Jain

GI Oncology · University Illinois

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.

    Jan 18, 2025DOI: 10.1245/s10434-024-16799-0Journal ArticleASO

    Written by: Jeremy SharibKristen E RhodinAnnie LiuSarah McIntyreAlex BartholomewSabran MasoudIsabel DeLauraNancy E KemenyAndrea CercekJames J HardingEileen M O'ReillyGhassan K Abou-AlfaDiane Reidy-LagunesLouise Catherine ConnellImane El DikaVinod P BalachandranJeffrey DrebinKevin C SoaresAlice C WeiT Peter KinghamMichael I D'AngelicaHope UronisJohn StricklerS David HsuMichael MorseSabino ZaniPeter J AllenWilliam R JarnaginMichael E Lidsky

    Find these authors on Roon

    DR
    Dr. Diane Reidy-Lagunes
    GI Oncology · Duke University

    Summary

    BACKGROUND: Randomized data suggest improved survival with adjuvant chemotherapy for biliary tract cancers; however, subset analyses of intrahepatic cholangiocarcinoma (IHC) show limited survival benefit. This study evaluated the impact of adjuvant chemotherapy on recurrence patterns and overall survival (OS) in patients with resected IHC.METHODS: Patients who underwent curative-intent resection for IHC were identified within a bi-institutional dataset and the National Cancer Database (NCDB). Patients were stratified by receipt of adjuvant chemotherapy. Site of first recurrence was categorized as liver only, regional, distant, or multifocal. Survival outcomes within each dataset were compared using Kaplan-Meier methods.RESULTS: In the bi-institutional dataset, 347 patients underwent resection for IHC, and 149 (43%) patients received adjuvant cytotoxic chemotherapy. Recurrence was observed in 222 (64.0%) patients. OS was similar between groups (adjuvant vs. observation: 42 vs. 49 months; p = 0.13), and did not differ in patients who received capecitabine specifically (p = 0.09) or in a risk-adjusted multivariable analysis. Recurrence-free survival was worse in those who received adjuvant chemotherapy (p = 0.04), although the liver was the most common site of recurrence in both groups (0.63). A similar analysis of 1159 resected IHCs from the NCDB also demonstrated no association between adjuvant chemotherapy and OS (49 vs. 57 months; p = 0.1).CONCLUSION: Adjuvant chemotherapy may not be associated with improved OS in IHC and did not have an impact on hepatic recurrence in this retrospective analysis. Future investigation to identify more effective adjuvant systemic regimens and/or explore the potential role of adjuvant liver-directed therapies to reduce hepatic recurrence that may improve OS for IHC is warranted.
    DRDr. Diane Reidy-Lagunes
    Leading Voice

    Dr. Diane Reidy-Lagunes

    Hematology & Oncology · Gastrointestinal Oncology
    Duke University
    dianereidylagunes